Some tumor cell lines secrete high concentrations of TGF␤ or IL-1. Similarly high concentrations of each of these cytokines cross-activate the other pathway: TGF␤ activates NFB, and IL-1␤ activates Smads. The IL-1 signaling components IRAK, MyD88, TRAF6, and TAK1 are all required for cross-activation of NFB by TGF␤. Knockdown experiments revealed that both TGF␤ receptor subunits are required for IL-1␤ to activate Smads, and the IL-1 receptor is required for TGF␤ to activate NFB. Coimmunoprecipitations showed that either TGF␤ or IL-1␤ stimulate ligand-dependent association of all three receptor subunits. Furthermore, cross-talk between the TGF␤ and IL-1 signaling pathways leads to dose-dependent cross-control of gene expression. These interactions provide new insight into biological responses to IL-1 and TGF␤ in the proximity of tumors that secrete high concentrations of these factors and probably also at sites of inflammation, where the local concentrations of these cytokines are likely to be high.
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cytokine receptors ͉ NFB ͉ Smad ͉ TLRs M embers of the TGF␤ superfamily regulate many developmental processes, and TGF␤ is involved in many human diseases, including cancer, where it functions, paradoxically, both as an antiproliferative factor and a tumor promoter (1) . The TGF␤ receptor (T␤R) is a complex of two single-pass transmembrane subunits, T␤RI and T␤RII, which contain intracellular serine/ threonine kinase domains. Ligand binding induces T␤RI and T␤RII to associate, leading to the phosphorylation of T␤RI by T␤RII, activating its kinase domain. Activated T␤RI then phosphorylates and activates the transcription factors Smad 2 and Smad 3 (1, 2) . TGF␤ can also activate other signaling proteins, including MAP kinases and, especially relevant to the work reported here, NFB (3, 4) . The balance between Smad activation and other signals is likely to help determine whether TGF␤ suppresses or promotes cancer (1, 2) .
IL-1 plays a crucial role in inflammation, stress, and disease (5, 6) . IL-1␣ or IL-1␤ bind to and activate the IL-1 receptor (IL-1R) (5) . IL-1R and the adaptor protein myeloid differentiation factor 88 (MyD88) interact through their intracellular domains (5) (6) (7) . The death domain of MyD88 then recruits the IL-1R-associated kinase (IRAK) to the receptor complex (5, 7) . IRAK is phosphorylated, dissociates from the receptor complex, and recruits tumor necrosis factor ␣ receptor-associated factor 6 (TRAF6), which in turn activates the downstream kinase TGF␤ activating kinase 1 (TAK1), eventually leading to the activation of inhibitor of NFB (IB), the phosphorylation and degradation of IB, and the activation of NFB (5) (6) (7) (8) . Responses to IL-1 are amplified through an autocrine loop. For example, astrocytoma cells respond to treatment with IL-1␤ by up-regulating mRNAs encoding IL-1␣ or IL-1␤, IL-1R, and tumor necrosis factor ␣ mRNAs (9) . Recent work reveals that this autocrine loop plays an important role in the development of resistance to the antitumor drug camptothecin, which induces the expression of IL-1␤ by activating NFB, inducing in turn the secretion of more IL-1␤ (10) . The IL-1R is a member of the large IL-1R/Toll-like receptor (TLR) superfamily, which is defined by a conserved intracellular domain. Each TLR can sense a distinct repertoire of conserved microbial molecules, and collectively they are able to detect most microbes (6) . For example, TLR2 recognizes lipoteichoic acid or zymosan, whereas TLR4 recognizes lipopolysaccharide (6) .
Previous reports from our laboratory revealed that TGF␤2 activates NFB at concentrations of Ϸ1 nM, considerably higher than the concentrations required to activate Smads (3, 11, 12) . Here we show that the activation of NFB by TGF␤2 requires MyD88, IRAK, TAK1, and TRAF6, four major components of IL-1␤ signaling, as well as the IL-1R. Furthermore, concentrations of IL-1␤ of Ϸ1 nM reciprocally activate Smads, and this crossactivation requires both TGF␤ receptor subunits. The physiological relevance of cross-activation by relatively high concentrations of IL-1 or TGF␤ is demonstrated by the observations that these cytokines are secreted at Ϸ1 nM levels by certain tumor cell lines.
Results

IRAK, MyD88, TRAF6, and TAK1 Are Required for TGF␤-Dependent
Activation of NFB. Using a B reporter-dependent luciferase assay, we find that the activation of NFB by TGF␤2 is deficient in IRAK-null or MyD88-null cells, compared with parental 293C6 cells (Fig. 1A) , indicating that these two major components of IL-1␤-dependent signaling are also needed for TGF␤2 to activate NFB. Furthermore, restoring IRAK or MyD88 to the deficient cells restored both IL-1␤-and TGF␤2-dependent NFB activation (Fig. 1B) . The inhibitory effects of dominant-negative constructs for TRAF6 or TAK1 showed that these two proteins are also likely to be required for TGF␤2 to activate NFB (Fig. 1C) . Because four important IL-1 signaling components seem to be required for TGF␤2 to activate NFB, it is likely that the entire IL-1 pathway is involved.
IL-1␤ Activates Smads. To test for reciprocal cross-activation, 293C6 and derived cell lines lacking IRAK or MyD88 were treated with 5 nM IL-1␤ or 0.2 nM TGF␤2 (positive control). The results show that Smad2 was activated within a very short time in all three cell lines ( Fig. 2 A and B) . The cells were pretreated with cycloheximide (CHX) for 1 h to show that the phosphorylation of Smad2 in response to IL-1␤ does not require new protein synthesis ( Fig. 2 A  and B) . Furthermore, as expected, IB␣ was not degraded in IL-1␤-treated IRAK-null or MyD88-null cells, compared with 293C6 parental cells, but Smad2 was still phosphorylated (Fig. 2 A  and B) , showing that neither IRAK nor MyD88 is required for IL-1␤ to activate Smads. Activation of Smads by IL-1␤ Is Dose Dependent and General. Previously, we determined the dose dependence for the activation of NFB in response to TGF␤2 (3) . To obtain comparable data for cross-activation, titrations with IL-1␤ were done in stable 293C6 cell lines expressing luciferase reporter constructs for NFB and Smads. Treatment for 4 h activated NFB half-maximally at Ϸ0.005 nM IL-1␤, and the activation reached a plateau at a concentration of Ϸ0.5 nM (Fig. 3A) . In contrast, the titration curve for Smad activation by IL-1␤ reached a plateau at Ϸ5 nM (Fig. 3B) . The concentration of IL-1␤ for half-maximum Smad activation was Ϸ1.25 nM, 250-fold higher than for NFB. However, activation of Smads was detected at concentrations of IL-1␤ as low as 0.2 nM (Fig. 3B and Western blot analysis data, data not shown). Because 293C6 cells overexpress the IL-1R and the IL-1R accessory protein (13, 14) , it is necessary to show that the activation of Smads by IL-1␤ is general. Therefore, we analyzed four additional cell lines. Smads can be activated by IL-1␤ in human fibroblast BJ and WI38 cells, human glioblastoma T98G cells, and human melanoma Mel29 cells (Fig. 3C ). Titrations revealed that 0.2 nM IL-1␤ is able to activate Smads substantially in BJ and Mel29 cells and detectably in WI38 and T98G cells (Fig. 3C ).
Cross-Signaling with TLR2. Because of the similarity of the IL-1R and TLR signaling pathways, it is logical to ask whether TGF␤ can use other members of the receptor superfamily to activate NFB. To address this question, we used 293 cells that, in contrast to 293C6 cells, have not been transfected with constructs encoding the IL-1R or the IL-1R accessory protein. Also, 293 cells do not express appreciable amounts of TLRs (15) . Constructs encoding flagtagged TLRs 1, 2, 4, 5, or 6 were transfected into 293 cells, and stable pools were checked for expression from the constructs (data not shown). We were not able to get enough expression of TLR4 in this experiment. TLRs 3, 7, 8, and 9 were not investigated because they are not expressed on the cell surface (6, 15) . The cells were transfected with a B reporter and treated with 2 nM TGF␤2 or 0.2 nM IL-1␤ for 4 h. As shown in Fig. 4 , TLR2 and possibly TLR5, but not TLR1 or TLR6, enhance the activation of NFB in response to TGF␤2. The results indicate that other members of the IL-1R superfamily can interact with TGF␤ receptors to catalyze receptormediated cross-talk.
Receptor Requirements for Cross-Signaling. Stable pools of 293C6 cells were generated that express siRNAs corresponding to T␤RI, T␤RII, Smad2, IL-1R, and Trp (tropomyosin, a control). Also included in the experiment were 293C6 cells expressing the IB super repressor of NFB (SR-IB), which carries serine-alanine mutations at positions 32 and 36 and therefore is not phosphory- lated and degraded in response to activation signals. The cells were pretreated with CHX for 1 h to inhibit protein synthesis, so that IB would not be resynthesized, and then treated with 2 nM TGF␤2 or 5 nM IL-1␤ for 1 h. Smad2 phosphorylation and IB␣ degradation were detected by Western blot analyses (Fig. 5A) . The same cells were transfected transiently with B-or Smad-dependent luciferase reporter constructs and then treated with 2 nM TGF␤2 or 5 nM IL-1␤ overnight (Fig. 5 B-E) . The data show that T␤RI and T␤RII, but not IL-1R, are required for TGF␤2 to activate Smads (Fig. 5 A,   D, and F) , and IL-1R, T␤RI, and T␤RII are all required for TGF␤ to activate NFB (Fig. 5 A, E, and F) and for IL-1␤ to activate Smads (Fig. 5 A, C, and F) . Furthermore, IL-1R, but not T␤RI or T␤RII, is required for IL-1␤ to activate NFB (Fig. 5 A, B, and F) . Additionally, Smad2 is not required for IL-1␤ or TGF␤2 to activate NFB (Fig. 5 A, B, and E) . The SR-B affected the IL-1␤/NFB and TGF␤2/NFB pathways (Fig. 5 A, B, and E) , but not the IL-1␤/Smad or TGF␤2/Smad pathways (Fig. 5 A, C, and D) . As summarized in Fig. 5F , cross-signaling requires not only the receptors that bind to the ligand that is applied to the cells, but also the receptors for the cross-signaling ligand.
Cross-Recruitment of Receptors After High-Dose Treatment with TGF␤2 or IL-1␤. Cells were treated with 0.2 or 4 nM TGF␤2 or with 0.25 or 5 nM IL-1␤ for 15 min, and the receptors were immunoprecipitated with anti-T␤RI, anti-T␤RII, or anti-IL-1R. IL-1R was strongly recruited to both T␤Rs at high concentrations of TGF␤2 or IL-1␤, and detectable cross-recruitment was also seen at lower concentrations (Fig. 6) . Similarly, both T␤RI and T␤RII were recruited strongly to IL-1R at high concentrations and detectably even at lower concentrations of TGF␤2 or IL-1␤. These data reveal that cross-talk between the TGF␤2 and IL-1␤ signaling pathways is likely to be mediated by ligand-dependent physical association of the receptors. (Fig. 7A) [a short gene list is found in supporting information (SI) Table 2 ]. Confirmation by Northern blot analysis of several examples from the microarray data showed that P8 and ELMO3 were induced well by the low concentration of IL-1␤ and the high concentration of TGF␤2, but were not induced well by the low concentration of TGF␤2 (Fig. 7 B and C) . Therefore, these two are likely to be NFB-responsive genes. Conversely, NUMBL and FAIM2 were induced by the low concentration of TGF␤2 and the high concentration of IL-1␤, but were not induced well by the low concentration of IL-1␤ (Fig. 7 B and C) , showing that these genes, which normally respond to TGF␤, are likely to be induced by IL-1␤ through the activation of Smads. Note that there is significant cross-activation of gene expression (Fig. 7) at cytokine concentrations that are consistent with those that stimulate cross-binding of the receptors (Fig. 6 ). ECM1 and GAGEB1 were not induced by low concentrations of IL-1␤ or TGF␤2, but were induced by high concentrations of either cytokine (Fig. 7) , suggesting that their expression might depend on the simultaneous activation of both the NFB and Smad pathways.
IL-1 Is Highly Expressed by Some Glioblastoma Cells.
In previous work, we showed that prostate cancer PC3 cells secrete high concentrations of TGF␤2 and that this secreted cytokine is responsible for the constitutive activation of NFB seen in these cells (3) . To demonstrate that large amounts of IL-1 are also secreted by tumor cells, we examined cell lines and primary isolates derived from glioblastomas. Table 1 shows that IL-1␣, IL-1␤, or both are secreted at high levels by some glioblastoma cells. In conditioned media from primary CCF3 cells, the concentration of IL-1␣ was 3.0 nM and that of IL-1␤ was 1.5 nM. In conditioned media from the U87 cell line, the concentration of IL-1␤ reached 1.2 nM, but that of IL-1␣ was lower. Therefore, some tumors secrete levels of TGF␤ or IL-1 that are well above the concentrations required to initiate cross-signaling.
Discussion
Mechanism of Cross-Talk. TGF␤2 and IL-1␤ activate their primary pathways at low concentrations and cross-activate the other pathways at higher concentrations. The mechanism involves ligand- dependent receptor-receptor interactions. Association of the two types of receptors might trigger cross-signaling in any of several ways. A major possibility is that aggregation of the receptors brings receptor-bound kinases into close proximity, allowing crossphosphorylation. In fact, a somewhat similar phenomenon has been reported in the IFN system, where the endogenous mouse IFN-␣ receptor 1 coimmunoprecipitates with IFN-␥ receptor 2 (16) . These cytokine receptors might exist in close proximity in a multimeric complex, for which the Taniguchi group proposed the term ''receptosome'' (17) . The components are probably brought together within lipid raft domains in the membrane that are rich in cholesterol and sphingolipids, allowing them to function efficiently in IFN-dependent signaling. It is possible that IL-1R and T␤RI/T␤RII also associate within lipid rafts. Di Guglielmo et al. (18) suggest that the T␤Rs are internalized into both caveolin-and early endosome antigen 1-positive vesicles and that they reside in both lipid raft and nonraft membrane domains.
Signaling Interactions Between TGF␤ and IL-1. To date, very few studies have documented connections between TGF␤-and IL-1-dependent signaling. Most of the published work shows that each cytokine antagonizes the other's effects. For example, Park et al. (19) showed that TGF␤ reduces the level of IL-1-induced cyclooxygenase-2 mRNA in mouse calvarial bone cells. Other studies report IL-1-mediated inhibition of TGF␤-dependent signaling in cocultured fibroblasts (20) and down-regulation of the expression of IL-1-induced TLR2 by TGF␤ in murine hepatocytes (21) . Choi et al. (22) reported that Smad6 negatively regulates IL-1R/TLR signaling through a direct interaction with the adaptor Pellino-1. Simultaneous positive and negative regulation of biological re- siTrp  siTβRI  siTβRII  siTβRI  siTβRII  siSmad2  siSmad2  SR-IκB  siTrp  siIL-1R  siIL-1R SR-IκB sponses has been seen before and may provide an opportunity for finely tuned regulation. A well known example is the stimulation by TNF-␣ of both pro-and antiapoptotic responses (23) .
Although TAK1 was first identified in the context of TGF␤-dependent signaling, it functions primarily as an essential component of the pathways activated by IL-1 (24) (25) (26) . The role of TAK1 in TGF␤-dependent signaling is controversial. For example, TAK1 has been reported to activate p38, allowing it to mediate a Smadindependent response to TGF␤ or even to interfere with the Smad function (27, 28) . A physical interaction between the inhibitory Smad6 and TAK1 has also been observed (29) . Furthermore, Benus et al. (30) suggested that IL-1 can inhibit TGF␤-dependent signaling directly through the phosphorylation of Smad3 by TAK1.
Physiological Relevance of Cross-Talk. Secretion of high concentrations of IL-1 has been documented in several instances. Elaraj et al. (31) showed that mRNAs encoding both IL-1␣ and IL-1␤ are highly expressed in metastases from patients with several different cancers and also in several tumor cell lines. IL-1␤ is highly expressed in non-small-cell lung carcinoma, colorectal adenocarcinoma, melanoma, and pancreatic carcinoma (31, 32) . The supernatant media from these cell lines stimulated a significant increase in the permeability of endothelial cell monolayers, a hallmark of early angiogenesis. Human pituitary adenoma HP75 cells generate Ϸ1 nM IL-1␣ when kept in culture for 72 h (33) . The same group tested 25 other primary cultures from human pituitary adenomas, removed during routine transphenoidal surgery, and reported that the secretion of IL-1␣ by these cells ranged from a concentration of 0.14 to 9.6 nM (33). Moreover, Fries et al. (34) reported that cultured monocytes from glioblastoma multiforme patients generated 2.2-2.8 nM IL-1␤ after 21 days in culture and that these cells survived for Ͼ250 days, whereas monocytes derived from controls generated 0.03-0.07 nM IL-1␤ after 21 days and that these cells survived for only 114 days. The authors suggested that enhanced IL-1␤ release increases the longevity of glioma-associated peripheral blood monocytes in vitro. Our current data contribute further to this story, showing that in human glioblastoma cells IL-1␣ and IL-1␤ are overexpressed. For example, CCF3 cells secreted 3.0 nM IL-1␣ and 1.5 nM IL-1␤ (Table 1) .
High concentrations of IL-1 may also drive the activation of Smads in inflammation. Persistent IL-1␤ signaling in glial cells is likely to make a key contribution to chronic inflammation of the brain (35) . Also, in a mouse model study, Joshi et al. (36) showed that, after treatment with lipopolysaccharide, IL-1␤ was induced and released, reaching a concentration of Ϸ0.14 nM in serum. The local concentration of IL-1␤ is likely to be much higher at a site of inflammation. TGF␤2 is secreted at a high concentration by a variety of cancer cell lines, including lines derived from prostate cancer, melanoma, and glioblastoma (3, 11, 12) . The high concentration of TGF␤2 (1.2 nM in medium from prostate cancer PC3 cells conditioned for 24 h) is responsible for the activation of NFB in these cells (3). The above examples strongly suggest that the phenomena we report here for both IL-1␤ and TGF␤ have important biological and pathological significance.
Cross-Talk at the Level of Gene Expression. Our analysis of gene expression suggests a concentration-dependent control by both TGF␤2 and IL-1␤. High concentrations of each of these cytokines activated genes that are normally activated by low concentrations of the reciprocal cytokine (Fig. 7A ). For example, 93 genes were induced 5-fold or more by a low concentration of TGF␤2. Of those, none was induced by a low concentration of IL-1␤, whereas 32 genes were induced by a high concentration of IL-1␤, indicating that high IL-1␤ can induce a subset of, but not all, TGF␤-specific genes. Furthermore, besides those 93 genes, an additional 69 genes were induced by a high concentration of TGF␤2. Of these, 49 genes were also induced by a low concentration of IL-1␤. On the other hand, 143 genes were induced 5-fold or more by a low concentration of IL-1␤. Of those, none was induced by a low concentration of TGF␤2, whereas 49 genes were induced by a high concentration of TGF␤2, indicating that high TGF␤2 can induce a subset of, but not all, IL-1␤-specific genes. Moreover, besides those 143 genes, an additional 62 genes were induced by a high concentration of IL-1␤. Of these, 32 genes were also induced by a low concentration of TGF␤2. Our data strongly suggest that cross-talk between the TGF␤ and IL-1␤ signaling pathways leads to dose-dependent cross-control of gene expression, which is likely to have an important effect on biological outcomes. An appreciation of these interactions provides new insight into responses to IL-1 and TGF␤ in the proximity of tumors that secrete high concentrations of these factors and probably also at sites of inflammation, where the local concentrations of these cytokines are also likely to be high. 
